Section
A double-blind randomized trial (PISCES) found daily fish-oil (EPA+DHA) 4 g reduced serious cardiovascular events by 43% versus corn-oil placebo in patients on maintenance hemodialysis over 3.5 years.
The FINE‑ONE Phase III trial found finerenone reduced urinary albumin-to-creatinine ratio (UACR) by 25% versus placebo in adults with type 1 diabetes and chronic kidney disease over six months, with safety broadly consistent with prior type
A pooled analysis of 58,816 participants shows SGLT2 inhibitors lower kidney disease progression, AKI, hospitalizations, and mortality across diabetes status and albuminuria levels, with larger absolute kidney benefits where UACR ≥200 mg/g.
The LIBERATE-D randomized trial found that a conservative, indication-triggered dialysis strategy increased unadjusted kidney-recovery rates at hospital discharge and shortened time to dialysis independence compared with routine thrice-week
A CKD-PC individual-patient meta-analysis found that 11% of outpatients and 35% of inpatients had eGFR by cystatin C ≥30% lower than creatinine-based eGFR; this discordance predicted higher mortality, cardiovascular events, heart failure an
LIBERATE‑D randomized hemodynamically stable patients with AKI to conservative vs conventional thrice‑weekly continuation of KRT; conservative discontinuation increased dialysis‑free recovery, shortened time to recovery, and reduced session
A SMART‑C meta‑analysis of 70,361 participants shows SGLT2 inhibitors reduce CKD progression and kidney failure across eGFR and albuminuria strata, including stage 4 CKD and low albuminuria.
A randomized cross‑over trial found that a 250‑ml net ultrafiltration challenge reliably identified preload‑independent critically ill patients who became preload‑dependent during continuous renal replacement therapy; a ≥5% calibrated cardi
A multicenter randomized trial in Japan found that rituximab significantly increased 49‑week relapse‑free survival versus placebo in adults with frequently relapsing or steroid‑dependent nephrotic syndrome, though infusion reactions were co
The BICARICU-2 randomized trial found that intravenous sodium bicarbonate in patients with severe metabolic acidemia and moderate-to-severe acute kidney injury did not reduce 90‑day mortality, but was associated with a substantial reduction
A systematic review of 17 randomized trials (n=4,259) found no consistent renoprotective effect from any vasopressor in septic shock. Heterogeneous definitions, underpowered studies, and reliance on RRT limit conclusions; standardized renal
In a double-blind RCT of 130 patients with refractory septic shock, terlipressin increased the proportion achieving MAP ≥65 mmHg with low catecholamine exposure at 6 hours versus placebo but did not change 28-day mortality; digital ischemia
In stable critically ill patients, contrast‑enhanced ultrasound (CEUS) renal perfusion metrics are reproducible; amplitude measures (RBV, PI) are more dose‑sensitive while mean transit time (mTT) shows greater robustness across infusion cha
In 911 critically ill patients on RCA-CKRT, citrate accumulation occurred in 17%. Pre-CKRT lactate strongly predicted accumulation (OR 2.34 per 1-unit increase on log scale); VIS was less discriminatory. Accumulation linked to liver dysfunc
A randomized trial found that maintaining high intraoperative urine output (≥3 ml·kg−1·h−1 or ≥200 ml·h−1) during cytoreductive surgery and cisplatin‑based HIPEC reduced 7‑day postoperative AKI from 39.3% to 21.4% and lowered major 30‑day c
A single-center study developed and internally validated a 48‑hour post‑liver transplant AKI risk model using five readily available preoperative and intraoperative variables (HE, alcohol cirrhosis, ALBI ≥ −1.78, operation time ≥560 min, an
This RCT shows dapagliflozin does not significantly affect bone metabolism or mineral density in lupus nephritis patients over 12 months, alleviating concerns about SGLT2 inhibitors’ bone safety in this population.
Dapagliflozin reduces left ventricular mass index in chronic kidney disease patients, revealing a key mechanism for cardioprotective effects of SGLT2 inhibitors and highlighting early treatment benefits.
This national registry study reveals that older adults with end-stage kidney disease (ESKD) exposed to high fine particulate pollution and racial/ethnic segregation face significantly elevated dementia risk, highlighting critical environmen
Deceased donor kidney transplantation improves survival compared to dialysis waitlisting, with benefits varying by donor kidney quality and recipient age. Low-risk kidneys yield the greatest survival gains, particularly in older recipients.
